Biosimilar infliximab for Behçet's syndrome: a case series.

Date
2019
Author
Hatemi, G.
Fresko, I.
Ozyazgan, Y.
Kutlubay, Z.
Mat, M. C.
Yurdakul, S.
Siva, A.
Hamuryudan, V.
Ucar, Didar
Dincses, E.
Esatoglu, S. N.
Ozguler, Y.
Uygunoglu, U.
Seyahi, E.
Melikoglu, M.
Metadata
Show full item record
Abstract
Objective. The efficacy and safety of biosimilar infliximab (bio-IFX) was shown in randomised controlled trials and it was approved for all indications of the reference product in several countries. However, a previous case series of 3 patients with Behcet's syndrome (BS) reported disappointing results. We aimed to share our experience with bio-IFX treatment in different types of organ involvement in patients with BS.
URI
http://hdl.handle.net/20.500.12627/59819
Collections